

Redx to present new scientific data at AACR 2017

03 Mar 2017

Redx Pharma Plc is pleased to announce that it will present two scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5, 2017, in Washington D.C., USA.

Session Date &
Time

April 5, 2017, 8:00 AM -12:00 PM Eastern Time

Session Title

Enzymes and Hormones and Metabolism in Tumor Immunity

Presentation Title

Development of 2nd generation indoleamine 2,3-dioxygenase 1 (IDO1) selective inhibitors

Session Location

Section 24

Abstract

5581 / 13

First author

Thomas Pesnot

Abstract online

<http://www.abstractsonline.com/pp8/#!/4292/presentation/6237>

Session Date
& Time

April 5, 2017, 8:00 AM -12:00 PM Eastern Time

Session Title

Oncogenes and Tumor Suppressors as Therapeutic Targets

Presentation
Title

Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS tumors

Session Date
& Time April 5, 2017, 8:00 AM -12:00 PM Eastern Time

Session
Location Section 6

Abstract # 5160 / 3

First author Helen Mason

Abstract online <http://www.abstractsonline.com/pp8/#!/4292/presentation/4116>

Dr Neil Murray, CEO of Redx, said: We're delighted to present new scientific data on two of our pre-clinical programs at the AACR meeting in April. As we are moving closer to the clinic with our most advanced programs, the Porcupine inhibitor RXC004 and the reversible BTK inhibitor RXC005, we continue to look for novel opportunities in several therapeutic classes in oncology and immunology.